PT  - JOURNAL ARTICLE
AU  - Kessler, Michael D.
AU  - Damask, Amy
AU  - O’Keeffe, Sean
AU  - Van Meter, Michael
AU  - Banerjee, Nilanjana
AU  - Semrau, Stefan
AU  - Li, Dadong
AU  - Watanabe, Kyoko
AU  - Horowitz, Julie
AU  - Houvras, Yariv
AU  - Gillies, Christopher
AU  - Mbatchou, Joelle
AU  - White, Ryan R.
AU  - Kosmicki, Jack A.
AU  - LeBlanc, Michelle G.
AU  - Jones, Marcus
AU  - ,
AU  - ,
AU  - Glass, David J.
AU  - Lotta, Luca A.
AU  - Cantor, Michael N.
AU  - Atwal, Gurinder S.
AU  - Locke, Adam E.
AU  - Ferreira, Manuel A. R.
AU  - Deering, Raquel
AU  - Paulding, Charles
AU  - Shuldiner, Alan R.
AU  - Thurston, Gavin
AU  - Salerno, Will
AU  - Reid, Jeffrey G.
AU  - Overton, John D.
AU  - Marchini, Jonathan
AU  - Kang, Hyun M.
AU  - Baras, Aris
AU  - Abecasis, Gonçalo R.
AU  - Jorgenson, Eric
TI  - Exome sequencing of 628,388 individuals identifies common and rare variant associations with clonal hematopoiesis phenotypes
AID  - 10.1101/2021.12.29.21268342
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2021.12.29.21268342
4099  - http://medrxiv.org/content/early/2022/01/01/2021.12.29.21268342.short
4100  - http://medrxiv.org/content/early/2022/01/01/2021.12.29.21268342.full
AB  - Clonal hematopoiesis (CH) refers to the expansion of certain blood cell lineages and has been associated with aging and adverse health outcomes. Here, we use exome sequence data on 628,388 individuals to identify 40,208 carriers of clonal hematopoiesis of indeterminate potential (CHIP). Using genome-wide and exome-wide association analyses, we identify 27 loci (24 novel) where germline genetic variation influences CH/CHIP predisposition, including missense variants in the DNA-repair gene PARP1 and the lymphocytic antigen coding gene LY75 that are associated with reduced incidence of CH/CHIP. Analysis of 5,194 health traits from the UK Biobank (UKB) found relationships between CHIP and severe COVID outcomes, cardiovascular disease, hematologic traits, malignancy, smoking, obesity, infection, and all-cause mortality. Longitudinal analyses revealed that one of the CHIP subtypes, DNMT3A-CHIP, is associated with the subsequent development of myeloid but not lymphoid leukemias, and with solid cancers including prostate and lung. Additionally, contrary to previous findings from the initial 50,000 UKB exomes, our results in the full sample do not support a role for IL-6 inhibition in reducing the risk of cardiovascular disease among CHIP carriers. Our findings demonstrate that CHIP represents a complex set of heterogenous phenotypes with shared and unique germline genetic causes and varied clinical implications.Competing Interest StatementAuthors declare that they are full time employees of Regeneron Pharmaceuticals Inc. Funding StatementThis study was funded by Regeneron Pharmacueticals, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank study: ethical approval for the UK Biobank was previously obtained from the North West Centre for Research Ethics Committee (11/NW/0382). The work described herein was approved by UK Biobank under application number 26041. GHS study: approval for DiscovEHR analyses was provided by the Geisinger Health System Institutional Review Board under project number 2006-0258.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDervied data (e.g. CHIP calls) produced in the present study are available upon reasonable request to the authors